DILANTIN INFATABS 50 MG
PHENYTOIN : 50 MG · DIN 00023698 · BGP PHARMA ULC
Health Canada status: MARKETED
What is DILANTIN INFATABS?
DILANTIN INFATABS 50 MG contains PHENYTOIN : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 00023698, held by BGP PHARMA ULC, supplied as TABLET (CHEWABLE) for ORAL administration. Health Canada currently lists it as marketed, status dated 02-Aug-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DILANTIN INFATABS used for?
Control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures. Not for absence seizures or metabolic-induced seizures.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00023698 |
|---|---|
| Brand name | DILANTIN INFATABS |
| Generic / active ingredient | PHENYTOIN : 50 MG |
| Manufacturer | BGP PHARMA ULC |
| Strength | 50 MG |
| Dosage form | TABLET (CHEWABLE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N03AB02 PHENYTOIN |
| AHFS class | 28:12.20 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 02-Aug-2023 |
| Original market date | 1964-12-31 00:00:00 |
How is it administered?
Adults: Start 2 Infatabs or 5mL (125mg/5mL) TID; adjust as needed. Pediatrics: 5 mg/kg/day in 2-3 divided doses, max 300 mg/day. Not for once-a-day dosing. Do not discontinue abruptly.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Section 11 listed in TOC but text ends at Section 7). Standard practice is 15-30°C.
How is it supplied?
Infatabs: Bottles of 100. Suspensions (30 mg/5 mL and 125 mg/5 mL): Bottles of 250 mL.
Contraindications
Hypersensitivity to phenytoin or hydantoins; delavirdine use; sick sinus syndrome, sinus bradycardia, SA block, 2nd/3rd degree AV block, QT prolongation, Adams-Stokes syndrome.
Warnings and precautions
Withdrawal may precipitate status epilepticus; risk of serious dermatologic/hypersensitivity reactions (DRESS, SJS/TEN); suicidal ideation; cardiac effects (bradycardia, arrest); hepatotoxicity.
Is PHENYTOIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by HIKMA CANADA LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N03AB02 PHENYTOIN. 7 of 14 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DILANTIN | 100 MG | CAPSULE | BGP PHARMA ULC | MARKETED | DIN 00022780 |
| DILANTIN | 30 MG | CAPSULE | BGP PHARMA ULC | MARKETED | DIN 00022772 |
| PHENYTOIN SODIUM | 100 MG | CAPSULE | AA PHARMA INC | MARKETED | DIN 02460912 |
| PHENYTOIN SODIUM INJECTION USP | 50 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02431378 |
| PHENYTOIN SODIUM INJECTION USP | 50 MG | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | DIN 00780626 |
| TARO-PHENYTOIN | 125 MG / 5 ML | SUSPENSION | TARO PHARMACEUTICALS INC | MARKETED | DIN 02250896 |
| DILANTIN INJ 50MG/ML | 250 MG / 5 ML | LIQUID | PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC. | CANCELLED POST MARKET | DIN 00245453 |
| DILANTIN-125 SUSPENSION | 125 MG / 5 ML | SUSPENSION | BGP PHARMA ULC | CANCELLED POST MARKET | DIN 00023450 |
| DILANTIN-30 SUSPENSION | 30 MG / 5 ML | SUSPENSION | BGP PHARMA ULC | CANCELLED POST MARKET | DIN 00023442 |
| NOVO-PHENYTOIN CAP 100MG | 100 MG | CAPSULE | NOVOPHARM LIMITED | CANCELLED POST MARKET | DIN 00037435 |
Who else supplies PHENYTOIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PHENYTOIN appears in 35 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.